Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 14 of 1,261
  1. US 12415856

    EGFR x CD28 multispecific antibodies

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  2. US 12414934

    Combination therapies

    Aardvark Therapeutics, Inc. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  3. US 12414953

    Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

    Prelude Therapeutics, Incorporated Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  4. US 12415861

    Anti C-MET antibodies

    CENTESSA PHARMACEUTICALS (UK) LIMITED Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  5. US 12415794

    Pyridazinone compounds and uses thereof

    EDGEWISE THERAPEUTICS, INC. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  6. US 12414963

    Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin

    Northwestern University Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  7. US 12414968

    Compositions comprising bacterially derived minicells and methods of using the same

    EnGeneIC Molecular Delivery Pty Ltd Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  8. US 12414981

    JNK inhibitors for use in treating and preventing neurodegenerative disorders

    Northwestern University Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  9. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  10. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  11. US 12415863

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  12. WO 2025186043

    FORMULATION PHARMACEUTIQUE POUR ANTICORPS ANTI-CCR8

    BAYER AG [DE] Β· Granted Sep 12, 2025 Β· Expires Sep 7, 2045

    granted
  13. US 2025281584

    ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] Β· Granted Sep 11, 2025 Β· Expires Sep 6, 2045

    granted
  14. US 12409227

    Cochleates made with soy phosphatidylserine

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  15. US 12409225

    Ras inhibitors

    Revolution Medicines, Inc. Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  16. US 12409206

    Use of cyclosporine analogues for treating fibrosis

    Hepion Pharmaceuticals, Inc. Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  17. US 12409224

    Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia

    The Regents of the University of Colorado, a Body Corporate Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  18. US 12409213

    Live attenuated oral vaccine against shigellosis and typhoid fever

    Sanaria Inc. Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  19. US 12410225

    Modulation of dendritic cell lineages

    Orionis Biosciences, Inc Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  20. US 12409197

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  21. US 12410170

    2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

    Arcus Biosciences, Inc. Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  22. US 12410184

    Crystalline forms of a menin inhibitor

    Kura Oncology, Inc. Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  23. US 12409220

    Conjugate polypeptides and vaccines for inducing immune responses

    The Regents of the University of California Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted
  24. US 12410132

    Antiplatelet drugs and uses thereof

    SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. Β· Granted Sep 9, 2025 Β· Expires Sep 4, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.